Arcutis Biotherapeutics ARQT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Key Insights
Critical company metrics and information
Latest Closing Price
$14.72Market Cap
$1.75 BillionPrice-Earnings Ratio
-12.69Total Outstanding Shares
118.64 Million SharesTotal Employees
342Dividend
No dividendIPO Date
January 31, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
3027 townsgate road, Westlake village, CA, 91361Homepage
https://www.arcutis.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-112.16 Million |
| Net Cash Flow From Operating Activities | $-112.16 Million |
| Net Cash Flow, Continuing | $-17.14 Million |
| Net Cash Flow | $-17.14 Million |
| Net Cash Flow From Financing Activities | $66.20 Million |
| Net Cash Flow From Investing Activities | $28.82 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Selling, General, and Administrative Expenses | $229.39 Million |
| Income Tax Expense/Benefit | $647,000 |
| Basic Average Shares | $120.96 Million |
| Income Tax Expense/Benefit, Deferred | $-152,000 |
| Operating Expenses | $305.81 Million |
| Income/Loss From Continuing Operations After Tax | $-140.04 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-140.05 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-11,000 |
| Comprehensive Income/Loss | $-140.05 Million |
| Comprehensive Income/Loss Attributable To Parent | $-140.05 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $348.89 Million |
| Fixed Assets | $1.04 Million |
| Equity Attributable To Parent | $157.54 Million |
| Noncurrent Assets | $13.07 Million |
| Current Assets | $335.82 Million |
| Current Liabilities | $81.01 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ARQT from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.